Cited by 235Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2

Zukin, Mauro, Barrios, Carlos H., Rodrigues Pereira, Jose, De Albuquerque Ribeiro, Ronaldo, de Mendonça Beato, Carlos Augusto, do Nascimento, Yeni Neron, Murad, Andre, Franke, Fabio A., Precivale, Maristela, de Lima Araujo, Luiz Henrique, Da Rocha Baldotto, Clarissa Serodio, Vieira, Fernando Meton, Small, Isabele A., Ferreira, Carlos G., Lilenbaum, Rogerio C.·2013·Journal of Clinical Oncology

DOI 10.1200/jco.2012.48.1911

Open this paper in CoChat — free account

Abstract

PURPOSE: To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. PATIENTS AND METHODS: In a multicenter phase III randomized trial, patients with advanced NSCLC, ECOG PS of 2, any histology at first and later amended to nonsquamous only, no prior chemotherapy, and adequate organ function were randomly assigned to P alone (500 mg/m(2)) or CP (area under the curve of 5 and 500 mg/m(2), respectively) administered every 3 weeks for a total of four cycles. The primary end point was overall survival (OS). RESULTS: A total of 205 eligible patients were enrolled from eight centers in Brazil and one in the United States from April 2008 to July 2011. The response rates were 10.3% for P and 23.8% for CP (P = .032). In the intent-to-treat population, the median PFS was 2.8 months for P and 5.8 months for CP (hazard ratio [HR], 0.46; 95% CI, 0.35 to 0.63; P < .001), and the median OS was 5.3 months for P and 9.3 months for CP (HR, 0.62; 95% CI, 0.46 to 0.83; P = .001). One-year survival rates were 21.9% and 40.1%, respectively. Similar results were seen when patients with squamous disease were excluded from the analysis. Anemia (grade 3, 3.9%; grade 4, 11.7%) and neutropenia (grade 3, 1%; grade 4, 6.8%) were more frequent with CP. There were four treatment-related deaths in the CP arm. CONCLUSION: Combination chemotherapy with CP significantly improves survival in patients with advanced NSCLC and ECOG PS of 2.

Integrity signals

Registry

Crossref · 10.1200/jco.2012.48.1911

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Quoix, E., Zalcman, G., Oster, J.-P., Westeel, V., Pichon, E., Lavolé, A., Dauba, J., Debieuvre, D., Souquet, P.-J., Bigay-Game, L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60780-0 · Cited by 566
Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)
Lilenbaum, R., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 443
Self-citation
Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
Lilenbaum, R., Axelrod, R. S., Thomas, S. P., Dowlati, A., Seigel, L., Albert, D., Witt, K., & Botkin, D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2720 · Cited by 176
Self-citation
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
Scagliotti, G. V., Kortsik, C., Dark, G. G., Price, A., Manegold, C., Rosell, R., O'Brien, M. E. R., Peterson, P. M., Castellano, D., Selvaggi, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.690.11.2 · Cited by 139
Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma
Akechi, T., Okamura, H., Nishiwaki, Y., & Uchitomi, Y. (2001) · Cancer · doi:10.1002/1097-0142(20011115)92:10 · Cited by 119
The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non–Small Lung Cancer
Scagliotti, G. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-9009 · Cited by 62

Flagged first, then by citations

Show all 7 references

Sorted by citations

Items 101–200 of 235

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
Gajra, A., Karim, N. A., Mulford, D. A., Villaruz, L., Matrana, M. R., Ali, H. Y., Santos, E. S., Berry, T., Ong, T. J., Sanford, A. R., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00253 · Cited by 14
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
Facchinetti, F., Pilotto, S., Metro, G., Baldini, E., Bertolaccini, L., Cappuzzo, F., Delmonte, A., Gasparini, S., Inno, A., Marchetti, A., et al. (2019) · Tumori Journal · doi:10.1177/0300891619857418 · Cited by 14
EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
Liu, A., Wang, X., Wang, L., Han, Z., Xiong, L., Gan, X., Wang, Q., & Tao, G. (2024) · BMC Cancer · doi:10.1186/s12885-024-13168-8 · Cited by 14
Efflux Transporter Variants as Predictors of Drug Toxicity in Lung Cancer Patients: Systematic Review and Meta-Analysis
Zaïr, Z. M., & Singer, D. R. J. (2016) · Pharmacogenomics · doi:10.2217/pgs-2015-0006 · Cited by 13
Relationship Between Physical and Psychological Status of Cancer Patients and Caregivers
Douglas, S. L., Daly, B. J., & Lipson, A. R. (2016) · Western Journal of Nursing Research · doi:10.1177/0193945916632531 · Cited by 14
Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer
Gentzler, R. D., & Johnson, M. L. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0212 · Cited by 12
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials
Iacovelli, R., Altavilla, A., Procopio, G., Sergio Bracarda, A., Santoni, M., Cascinu, S., & Cortesi, E. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.20 · Cited by 12
The Treatment of Advanced Lung Cancer in the Elderly
Presley, C. J., & Lilenbaum, R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000145 · Cited by 12
Self-citation
Pemetrexed and carboplatin combination therapy followed by pemetrexed maintenance in Japanese patients with non-squamous non-small cell lung cancer: A subgroup analysis of elderly patients
Nogami, N., Nishio, M., Okamoto, I., Enatsu, S., Suzukawa, K., Takai, H., Nakagawa, K., & Tamura, T. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.09.003 · Cited by 12
Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
Kwan, T. Y., & Chowdhury, E. H. (2021) · Medicina · doi:10.3390/medicina57111252 · Cited by 10
Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study
Gow, C., Hsieh, M., Chen, Y., Liu, Y., Wu, S., & Shih, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1113696 · Cited by 10
Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer
Jo, H., Park, S., Kim, N. E., Park, S. Y., Ryu, Y. J., Chang, J. H., & Lee, J. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092391 · Cited by 10
Comparing single‐agent with doublet chemotherapy in first‐line treatment of advanced non‐small cell lung cancer with performance status 2: A meta‐analysis
Luo, L., Hu, Q., Jiang, J., Yang, X., Dinglin, X.-X., Lin, X., & Yao, H. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12359 · Cited by 10
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
Langer, C. J., Kim, E. S., Anderson, E. C., Jotte, R. M., Modiano, M., Haggstrom, D. E., Socoteanu, M. P., Smith, D. A. B., Dakhil, C. S. R., Konduri, K., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00262 · Cited by 10
Non-small Cell Lung Cancer
Tantraworasin, A., Kongkarnka, S., Lertprasertsuke, N., Wannasopha, Y., Euathrongchit, J., Suksombooncharoen, T., Saeteng, S., Siwachat, S., & Chewaskulyong, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-16245-0_9 · Cited by 10
A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC
Piha-Paul, S. A., Simon, G. R., Belani, C. P., Chao, H., Gaspar, K. J., Lee, B., & Dowlati, A. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100408 · Cited by 10
Concurrent cetuximab and postoperative radiation in resected high‐risk squamous cell carcinomas of the head and neck: A single‐institution experience
Araki, D., Redman, M. W., Martins, R. G., Eaton, K. D., Baik, C. S., Chow, L. Q. M., Goulart, B. H. L., Lee, S. Y., Santana-Dávila, R., Liao, J. J., et al. (2016) · Head & Neck · doi:10.1002/hed.24437 · Cited by 10
Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer
Miyahara, T., Sueoka‐Aragane, N., Iwanaga, K., Ureshino, N., Komiya, K., Nakamura, T., Nakashima, C., Abe, T., Matsunaga, H., & Kimura, S. H. (2017) · Medical Oncology · doi:10.1007/s12032-017-1053-8 · Cited by 10
Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., van der Wekken, A. J., & van Geffen, W. H. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013382.pub2 · Cited by 8
Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
Hosokawa, S., Ichihara, E., Harada, D., Kuyama, S., Inoue, K., Gemba, K., Ichikawa, H., Kato, Y., Oda, N., Oze, I., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02164-2 · Cited by 9
Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy
Hatic, H., Hearld, K. R., Das, D. G., & Deshane, J. S. (2022) · Cancers · doi:10.3390/cancers14235954 · Cited by 11
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2
Shaverdashvili, K., Reyes, V. E., Wang, H., Mehta, D. R., Marsh, C., Waas, J. K., VanderWeele, R. A., Peracha, S. M., Liang, H., Socinski, M. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102317 · Cited by 9
Engaging Patients with Late-Stage Non-Small Cell Lung Cancer in Shared Decision Making about Treatment
Myers, R. E., Advani, S., Myers, P., Selvan, P., Garber, G. D., Worster, B. K., Flomenberg, N., Chapman, A. E., & Zinner, R. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11100998 · Cited by 9
Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status
Fujio, T., Nakashima, K., Naito, T., Kobayashi, H., Omori, S., Wakuda, K., Ono, A., Kenmotsu, H., Murakami, H., & Takahashi, T. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2018.1559941 · Cited by 9
Cytotoxic chemotherapy in advanced non–small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice
Kancharla, H., Naresh, G., Pathak, N., Vandidassane, I., Khurana, S., Pushpam, D., Jain, D., Kumar, S., Pathy, S., Mohan, A., et al. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100550 · Cited by 9
Physiologically driven nanodrug delivery system for targeted lung cancer treatment
Zhang, S., Li, X., Liu, Y., Li, H., & Zhang, Z. (2024) · Exploration of Medicine · doi:10.37349/emed.2024.00221 · Cited by 9
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
Лактионов, К. К., Артамонова, Е. В., Borisova, T. N., Breder, V. V., Маркович, Б. Ю., Vladimirova, L. Y., Волков, Н. М., Ергнян, С. М., Жабина, А. С., Kononets, P. V., et al. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.3.201848 · Cited by 9
Multicentric retrospective analysis of platinum‐pemetrexed regimens as first‐line therapy in non‐squamous non‐small cell lung cancer patients: A “snapshot” from clinical practice
Cortellini, A., Gambale, E., Cannita, K., Brocco, D., Parisi, A., Napoleoni, L., Masedu, F., Irtelli, L., Tursi, M. D., Natoli, C., et al. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12570 · Cited by 8
Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia
Khan, G. N., Orchard, K. H., & Guinn, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020134 · Cited by 8
Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients
Tseng, Y.-H., Tseng, Y., Lin, Y.-H., Lee, Y.-C., Perng, R.-P., Whang‐Peng, J., & Chen, Y.-M. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0352 · Cited by 8
Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper
Battisti, N. M. L., Liposits, G. I., de Glas, N. A., Gomes, F., Baldini, C., & Mohile, S. G. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00958-z · Cited by 7
High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
Prabhash, K., Gota, V. S., Kavathiya, K., Doshi, K., Damodaran, Gurjar, M., Joshi, A., & Noronha, V. (2014) · Cancer Management and Research · doi:10.2147/cmar.s60177 · Cited by 7
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301)
Guetz, G. D., Landre, T., Westeel, V., Milleron, B. J., Vaylet, F., Urban, T., Barlési, F., Souquet, P.-J., Debieuvre, D., Braun, D., et al. (2015) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2015.02.002 · Cited by 7
A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)
Hata, A., Katakami, N., Fujita, S., Nanjo, S., Takeshita, J., Tanaka, K., Kaneda, T., Nishiyama, A., Nishimura, T., Nakagawa, A., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2755-2 · Cited by 7
A machine learning approach to predicting short-term mortality risk in patients starting chemotherapyPreprint
Elfiky, A. A., Pany, M. J., Parikh, R. B., & Obermeyer, Z. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/204081 · Cited by 7
Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer
Bakirhan, K., Sharma, J. N., Perez-Soler, R., & Cheng, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0388-2 · Cited by 6
Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?
Ikeda, S., Naito, T., Miura, S., Ito, K., Furuya, N., Misumi, T., Ogura, T., & Kato, T. (2022) · Cancers · doi:10.3390/cancers14194861 · Cited by 6
Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2
Schluckebier, L. F., Garay, O. U., Zukin, M., & Ferreira, C. G. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.015 · Cited by 6
Self-citation
Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events
Lawson, J., Switchenko, J. M., McKibbin, T., & Harvey, R. D. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1759 · Cited by 6
Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer
Nakashima, K., Akamatsu, H., Murakami, H., NIWA, T., Iwamoto, Y., Ozawa, Y., Yokoyama, T., Shoda, H., Yamamoto, N., Yoshioka, H., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13263 · Cited by 6
Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
Zhao, X., Yu, H., Zhao, J., Wu, X., Sun, S., Luo, Z., Wang, H., Qiao, J., Chang, J., & Wang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21186 · Cited by 6
Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
Young, P. A., Márquez‐Garbán, D. C., Noor, Z. S., Moatamed, N. A., Elashoff, D. A., Grogan, T., Romero, T., Sasano, H., Saito, R., Rausch, R., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100150 · Cited by 6
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
Wislez, M., Domblides, C., Greillier, L., Mazières, J., Monnet, I., Kiakouama-Maleka, L., Quantin, X., Spano, J., Ricordel, C., Fraisse, P., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.013 · Cited by 6
Carboplatin plus pemetrexed for the elderly incurable chemo‐naive nonsquamous non–small cell lung cancer: Meta‐analysis
Ito, M., Horita, N., Nagashima, A., & Kaneko, T. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12837 · Cited by 6
Updates in oncology
Sculier, J. P., Meert, A. P., & Berghmans, T. (2014) · European Respiratory Review · doi:10.1183/09059180.00009013 · Cited by 6
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Mark, M. T., Froesch, P., Gysel, K., Rothschild, S. I., Addeo, A., Ackermann, C. J., Chiquet, S., Schneider, M., Ribi, K., Maranta, A. F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113600 · Cited by 5
Aktualisierte Therapieempfehlung metastasiertes nicht kleinzelliges Lungenkarzinom
Reinmuth, N., Gröschel, A., Schumann, C., Sebastian, M., Wiewrodt, R. G., & Reck, M. (2017) · Pneumologie · doi:10.1055/s-0043-118904 · Cited by 6
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer
Afzal, M. Z., Dragnev, K. H., & Shirai, K. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.03.09 · Cited by 5
Real-World Outcomes and Value of First-Line Therapy for Metastatic Non-Small Cell Lung Cancer†
Byfield, S. D., Chastek, B. J., Korrer, S., Horstman, T., Malin, J. K., & Newcomer, L. N. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1827415 · Cited by 5
[Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer in the Elderly (2022 Edition)].
(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.101.25 · Cited by 5
Analysis of prognosis and treatment decisions for patients with second primary lung cancer following esophageal cancer
Li, J., Li, H., Wu, Q., Zhou, H., Li, Y., Li, Y., & Li, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.777934 · Cited by 5
Dose Escalation and Pharmacokinetic Study of Carboplatin plus Pemetrexed for Elderly Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer: Kumamoto Thoracic Oncology Study Group Trial 1002
Sakata, S., Sasaki, J., Saeki, S., Hamada, A., Kishi, H., Nakamura, K., Tanaka, H., Notsute, D., Sato, R., Saruwatari, K., et al. (2014) · Oncology · doi:10.1159/000369255 · Cited by 5
Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.
Kimura, T., Taniguchi, H., Watanabe, N., Saka, H., Kogure, Y., Shindo, J., Ogasawara, T., Kojima, E., Hasegawa, Y., Yamamoto, M., et al. (2016) · PubMed · Cited by 5
Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States
Chen, L., Kim, J. S., Antonio, B. S., Zhu, Y. E., Mitchell, L., & John, W. J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.11.11 · Cited by 5
ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
Singh, A. K., Kapoor, A., Noronha, V., Patil, V., Menon, N. S., Mahajan, A., Janu, A., Parandare, N., Kaushal, R., & Prabhash, K. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1407 · Cited by 5
Treatment dilemma in the care of older adults with advanced lung cancer
Gajra, A., Anand, A., Loh, K. P., & Mohile, S. G. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.73 · Cited by 4
Effect of maternal weight on accuracy of maternal and physician estimate of fetal weight.
Nguyen, T., Hawkins, C. J., Amon, E., & Gavard, J. A. (2013) · PubMed · Cited by 4
Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study
Pathak, N., Garg, R. K., Khurana, S., Kumar, S., Kumar, A., Pushpam, D., Khan, M. A., Mohan, A., Pathy, S., Yadav, M., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04617-1 · Cited by 4
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Pacheco, J. M. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.03 · Cited by 4
Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease
Gao, G., Zhou, C., Huang, Y., Hong, Z., Yu, P., Chen, Y., Gao, J., Zhang, K., Xie, Z., Zhang, J., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-371 · Cited by 4
Second-Line Treatment Selection in Patients With Non–Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians
Girard, N., Corral, J., Cortinovis, D. L., & Heigener, D. F. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.004 · Cited by 4
First-Line Treatment of Nonsquamous NSCLC Using Gemcitabine: A Retrospective Study of Real-Life Practice
Kohútek, F., Stratena, M., Rosík, A., Tamášová, M., & Bystrický, B. (2016) · Lung Cancer Management · doi:10.2217/lmt-2016-0011 · Cited by 4
Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies
Okamoto, I., Schuette, W., Stinchcombe, T. E., Pereira, J. R., Antonio, B. S., Chen, J., Liu, J., John, W. J., & Zinner, R. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1297701 · Cited by 4
Management of Metastatic Nonsmall Cell Lung Cancer in Elderly
Sheth, H., Kumar, P., & Limaye, S. A. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1732784 · Cited by 3
Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database
Ikeda, S., Ogura, T., Miyaoka, E., Sekine, I., Shukuya, T., Takayama, K., Inoue, A., Okamoto, I., Seike, M., Takahashi, K., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108102 · Cited by 3
Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet
Paulus, A., Žemaitis, M., Cicėnas, S., Zvirbule, Z., Sanfridson, A., Millrud, C. R., Magnusson, S., Losic, N., Tersago, D., Garcia‐Ribas, I., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108664 · Cited by 3
Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective
Andrew, P., Vickers, M. M., O’Connor, S., Valdes, M., & Tang, P. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0056 · Cited by 3
A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy
Dong, S., Ou, W., Zhong, Y., Zhu, X., Cai, Q., Zhang, J., Ran, F., Qian, Y., Wang, J., & Hu, S. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-79 · Cited by 3
Association Between Change in Quality of Life and Survival in Advanced Non-Small-Cell Lung Cancer
erdem, R. (2022) · Turkish Journal of Oncology · doi:10.5505/tjo.2022.3375 · Cited by 3
Clinical Effect of Treatment with Metformin for Type 2 Diabetes on Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: A Retrospective Study
Wang, Y., Sun, Y., Hu, J., & Ma, H. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s495449 · Cited by 3
COVID-19 and oncological disease
Šálek, T., Slopovský, J., Porsok, S., Pazderová, N., Mináriková, Z., Zomborska, E., & Špánik, B. (2021) · Klinicka onkologie · doi:10.48095/ccko2021211 · Cited by 3
Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC
Strimpakos, A. S., Banerji, U., Thavasu, P., Tsilimagou, A., Psyrri, A. K., & Syrigos, K. (2015) · Oncology · doi:10.1159/000371711 · Cited by 3
Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study
Chen, L., Antonio, B. S., Yan, Y., Chen, J., Goodloe, R., & John, W. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1297700 · Cited by 3
Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów
Jassem, J., Biernat, W., Bryl, M., Chorostowska‐Wynimko, J., Dziadziuszko, R., Krawczyk, P. A., Kordek, R., Kowalski, D. M., Krzakowski, M. J., Olszewski, W. T., et al. (2014) · Advances in respiratory medicine · doi:10.5603/piap.2014.0019 · Cited by 3
Lung Cancer: Diagnosis and Treatment Approach
Tantraworasin, A., Suksomboonchroen, T., Wannasopha, Y., Kongkarnka, S., Saeteng, S., Lertprasertsuke, N., Euathrongchit, J., & Chewaskulyong, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-21683-6_7 · Cited by 3
Minimize Toxicity or Preserve Efficacy? A Delicate Trade-Off in the Management of Older Patients With Lung Cancer
Owonikoko, T. K., & Ramalingam, S. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5033 · Cited by 3
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty
Thomas, T. S., Patel, B. G., Mitchell, J. D., Whitmer, A. L., Knoche, E., & Gupta, P. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.004 · Cited by 2
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)
Facchinetti, F., Camerini, A., Bennati, C., Bordi, P., Carlo, E. D., Mazzoni, F., Metro, G., Bertolini, F., Longo, L., Ricciardi, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108580 · Cited by 2
The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions
Semenova, Y. M., Burkitbayev, Z. K., Kalibekov, N., Digay, A., Zhaxybayev, B., Shatkovskaya, O., Khamzina, S., Zharlyganova, D., Kuanysh, Z., & Manatova, A. (2025) · Cancers · doi:10.3390/cancers17132143 · Cited by 3
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L
Kataoka, S., Shukuya, T., Ohtsu, H., Miyawaki, T., Fujimoto, D., Hayashi, H., Toi, Y., Yokoyama, T., Kato, T., Yamaguchi, T., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.12.002 · Cited by 2
Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy
Xu, B., Shi, J., Lu, W., Wu, Y., & Dong, X. (2023) · Pancreas · doi:10.1097/mpa.0000000000002214 · Cited by 2
Focus on Recommendations for the Management of Non-small Cell Lung Cancer
Lavaud, P., Besse, B., de Baère, T., Deschamps, F., Mussot, S., Pechoux, C. L., Caramella, C., Mercier, O. M., Mezquitta, L., Botticella, A., et al. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02222-9 · Cited by 2
Cytotoxic Chemotherapy for Non-small Cell Lung Cancer
Park, B.-B. (2014) · Hanyang Medical Reviews · doi:10.7599/hmr.2014.34.1.31 · Cited by 2
Defining the Issues in the Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer
Gajra, A. (2015) · Lung Cancer Management · doi:10.2217/lmt.14.42 · Cited by 2
Maladie oligométastatique dans le cancer bronchique non à petites cellules
Quoix, É., Milleron, B. J., & Beau‐Faller, M. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70605-6 · Cited by 2
Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.
Zhou, C., Qin, Y.-Y., Xie, Z., Zhang, J., Ouyang, M., Li, S., & Chen, R. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2014.12.19 · Cited by 2
Pemetrexed as indispensable drug for the treatment of non-squamous non-small cell lung cancer; the role in induction and maintenance therapy
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.157 · Cited by 2
Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
Zhu, Y., Xing, P., Wang, S., Ma, D., Mu, Y., Li, X., Xu, Z., & Li, J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12594 · Cited by 2
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016
Gelsomino, F., Boni, L., Tiseo, M., Ricciardi, S., Rocco, D., Cortinovis, D. L., Proietto, M., Cogoni, A. A., Pasello, G., Camerini, A., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108059 · Cited by 1
Targeted Therapy and Immunotherapy in Elderly Patients with Metastatic Colorectal Cancer
Huang, W., & Liu, Y. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01326-4 · Cited by 1
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
Gounant, V., Greillier, L., Mascaux, C., Pinquie, F., Carmier, D., Moreau, L., Roch, B., Debieuvre, D., Dhalluin, X., Leprieur, E. G., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100908 · Cited by 1
Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status
Evans, T. L. (2015) · American Journal of Hematology / Oncology® · Cited by 1
Defining standard of care for performance status 2—don't rush
Gridelli, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.134 · Cited by 1
Pemetrexed in Non-Small-Cell Lung Cancer
Dediu, M., Alexandru, A., & Bratu, F. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.16 · Cited by 1
Head and Neck Cancer in the Older Adult: Approaches in Evaluation and Management
Maggiore, R. J. (2014) · Current Geriatrics Reports · doi:10.1007/s13670-014-0089-2 · Cited by 1
Elderly selection on geriatric index assessment
Tomasini, P., Mascaux, C., & Barlési, F. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.05.61 · Cited by 1
A phase II study of carboplatin and pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer
Nishizawa, H., Horiike, A., Saito, R., Ohyanagi, F., Kudo, K., Yanagitani, N., Tambo, Y., Kitazono, S., Kobayashi, H., & Nishio, M. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.08.003 · Cited by 1
New 3-aminorhodanine derivatives: Synthesis, characterization, docking study and biological activates
Khalaf, N. A. D., Hasan, H. A., & Ali, K. F. (2023) · F1000Research · doi:10.12688/f1000research.141708.1 · Cited by 1
Lung Cancer in Older Adults
Frith, A. E., & Baggstrom, M. Q. (2014) · Current Geriatrics Reports · doi:10.1007/s13670-014-0092-7 · Cited by 1
A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit
Khosravi, A., Salimi, B., Esfahani‐Monfared, Z., Seifi, S., & Mirtavoos‐Mahyari, H. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.10.2973 · Cited by 1

Authors: Zukin, M., Barrios, C. H., Rodrigues Pereira, J., De Albuquerque Ribeiro, R., de Mendonça Beato, C. A., do Nascimento, Y. N., Murad, A., Franke, F. A., Precivale, M., de Lima Araujo, L. H., Da Rocha Baldotto, C. S., Vieira, F. M., Small, I. A., Ferreira, C. G., & Lilenbaum, R. C.
Affiliations: Hospital Haroldo Juaçaba (BR)
Mauro Zukin, Luiz Henrique de Lima Araujo, Clarissa Serodio Da Rocha Baldotto, Fernando Meton Vieira, Isabele A. Small, and Carlos G. Ferreira, Instituto Nacional do Cancer, Rio de Janeiro; Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre; Jose Rodrigues Pereira, Instituto do Cancer Arnaldo Vieira Carvalho; Maristela Precivale, PGS Medical Statistics, Sao Paulo; Ronaldo De Albuquerque Ribeiro, Instituto do Cancer do Ceara, Fortaleza; Carlos Augusto de Mendonça Beato,...
ORCID: Zukin, Mauro
Barrios, Carlos H.
Franke, Fabio A.
Small, Isabele A.
Ferreira, Carlos G.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2013-08-10
Volume: 31
Issue: 23
Pages: 2849-2853
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2012.48.1911
OpenAlex: W2097268198
Cited by: 235
References: 7
Citations by year: 2026: 2 · 2025: 11 · 2024: 8 · 2023: 12 · 2022: 16 · 2021: 14 · 2020: 20 · 2019: 20 · 2018: 26 · 2017: 17 · 2016: 25 · 2015: 26 · 2014: 28 · 2013: 9
FWCI: 23.87
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, pemetrexed, carboplatin, combination chemotherapy, first-line therapy, overall survival, progression-free survival, anemia, neutropenia, non-relapse mortality
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Prospective Studies, Survival Rate, Carboplatin, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks